# Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Article · Mikhail Kosiborod, Mark Colquhoun Petrie, Barry A. Borlaug, Javed Butler, Melanie Jane Davies, G. Kees Hovingh, Dalane W. Kitzman, Daniél V. Møller, Marianne Bach Treppendahl, Subodh Verma, Thomas Jensen, Karoline Liisberg, Marie L.S. Lindegaard, Walter P. Abhayaratna, Fozia Zahir Ahmed, Tuvia Ben Gal, Vijay Chopra, Justin Adrian Ezekowitz, Michael L.X. Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtěch Melenovský, Béla Péter Merkely, Julio E. Núñez, Eduardo Roque Perna and 7 more

- Archive id: doi:10.1056/nejmoa2313917
- Published: 2024-03-28
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2313917
- PMID: 38587233
- Citations: 753
- Source URL: https://doi.org/10.1056/nejmoa2313917
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.